| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | BUY | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.08▲ | 2.07▲ | 2.07▲ | 2.09▼ | 1.99▲ |
| MA10 | 2.07▲ | 2.07▲ | 2.07▲ | 2.03▲ | 2.08▲ |
| MA20 | 2.08▲ | 2.08▲ | 2.07▲ | 1.96▲ | 2.49▼ |
| MA50 | 2.07▲ | 2.07▲ | 2.03▲ | 2.06▲ | 2.19▼ |
| MA100 | 2.07▲ | 2.01▲ | 1.96▲ | 2.38▼ | 3.02▼ |
| MA200 | 2.02▲ | 1.96▲ | 2.00▲ | 2.01▲ | 19.36▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▼ | -0.001▼ | -0.002▼ | 0.032▲ | -0.056▼ |
| RSI | 54.266▲ | 56.327▲ | 58.092▲ | 53.508▲ | 47.869▼ |
| STOCH | 50.579 | 33.565 | 25.000 | 85.944▲ | 30.167 |
| WILL %R | -50.000 | -50.000 | -50.000 | -17.241▲ | -77.333▼ |
| CCI | 58.137 | 75.310 | 124.324▲ | 77.918 | -48.923 |
|
Thursday, May 01, 2025 12:10 PM
NRx Pharmaceuticals (NASDAQ: NRXP) announced it has received a $4.3 million New Drug Application filing fee waiver from the FDA for NRX-100, its pre ...
|
|
Saturday, April 26, 2025 05:01 PM
Short interest is currently not available. Nasdaq provides information of company’s short interest and the average days it takes to cover them. Short interest and days to cover can be used to ...
|
|
Monday, April 21, 2025 05:00 PM
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx Pharmaceuticals", or the "Company"), a clinical-stage biopharmaceutical company, and HOPE Therapeutics, Inc., ("HOPE ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 02/05/25 | 2.095 | 2.095 | 2.07 | 2.09 | 12,243 |
| 01/05/25 | 2.11 | 2.13 | 2.0278 | 2.08 | 74,205 |
| 30/04/25 | 2.08 | 2.12 | 1.97 | 2.12 | 243,181 |
| 29/04/25 | 2.075 | 2.09 | 2.06 | 2.06 | 93,430 |
| 28/04/25 | 2.11 | 2.11 | 2.01 | 2.10 | 58,704 |
| 25/04/25 | 2.07 | 2.096 | 2.03 | 2.07 | 65,449 |
| 24/04/25 | 1.98 | 2.10 | 1.9501 | 2.07 | 107,179 |
| 23/04/25 | 1.95 | 2.07 | 1.9301 | 1.98 | 54,702 |
| 22/04/25 | 1.88 | 1.95 | 1.8753 | 1.91 | 31,133 |
| 21/04/25 | 1.88 | 1.97 | 1.85 | 1.87 | 94,198 |
|
|
||||
|
|
||||
|
|